Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Oncology·MeSH: Lymphoma, Mantle-Cell
Prevalence
5.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| kte-c19 | Kite Pharma, Inc. (KITE) |
Frequently asked questions
How many drugs are in development for Relapsed/Refractory Mantle Cell Lymphoma (MCL)?
BioSniper tracks 1 drug in development for Relapsed/Refractory Mantle Cell Lymphoma (MCL) across 1 company.
How many clinical trials target Relapsed/Refractory Mantle Cell Lymphoma (MCL)?
There are 1 clinical trial targeting Relapsed/Refractory Mantle Cell Lymphoma (MCL) tracked by BioSniper.
What is the prevalence of Relapsed/Refractory Mantle Cell Lymphoma (MCL)?
The estimated prevalence of Relapsed/Refractory Mantle Cell Lymphoma (MCL) is approximately 5.0 per 100,000 population.
Deep-dive into Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis